Live Chat ×
Skip to main content

Incorporating TRK Inhibition Into the Treatment Paradigm: The Pathologist's Role

Please follow the link below to access Incorporating TRK Inhibition Into the Treatment Paradigm: The Pathologist's Role on Medscape's website. This program was developed through the collaboration between the United States and Canadian Academy of Pathology (USCAP) and Medscape at the 2019 USCAP Annual Meeting.

Authors: Eric Q. Konnick, MD; Robert C. Doebele, MD, PhD; Jaclyn F. Hechtman, MD
CME / ABIM MOC Released: 05/08/2019
Valid for Credit Through: 05/08/2020

Course Description
The goal of this activity is to increase pathologists' knowledge of a new druggable target in oncology and to improve their performance identifying patients for and implementing NTRK gene fusion testing in daily practice.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Have increased knowledge regarding the epidemiology of NTRK gene fusions in oncology, within and across different types of solid tumots
  • Have increased knowledge regarding clinical use of tropomyosin receptor kinase (TRK) inhibitors in adult and pediatric patients whose tumors harbor an NTRK gene fusion
  • Have greater competence related to collaborating with medical oncologists to identify appropriate patients for NTRK gene fusion testing
  • Have greater competence related to recognizing best practices for NTRK gene fusion testing to inform clinical decision making

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact